Research & Development
Advanced Control Strategies for Nitrosamine Impurities
Nitrosamine Impurities Overview
We conduct focused, safety-driven R&D on N-nitrosamines & related nitroso impurities to protect patient safety, ensure regulatory compliance & support our customers (API & formulation manufacturers) in managing these compounds across the supply chain.
Our work covers the full lifecycle: Risk Assessment → Analytical Method Development → Control & Mitigation Strategies → Stability & Batch Monitoring → Regulatory Documentation.
Examples of compounds we study include: NDMA, NDEA, NEIPA, NDIPA, NDBA, NMBA, NPYR, NPIP, NMOR, NDPA, NDPhA, NMPhA, NEMA, NBnMA, NDBnA, NDELA, NDIBA, NEPhA, DNPIPZ, N-nitrosomethylpropylamine, N-nitrosomethylisopropylamine, N-nitrosomethyl-tert-butylamine, NMU, MNNG, MNPIPZ, NDCYCA, N-nitrosovarenicline, N-nitroso vortioxetine & vortioxetine sulfoxide.
Our R&D Focus Areas
- Systematic risk screening of APIs, intermediates, excipients, solvents, reagents & manufacturing steps that could lead to nitrosamine formation or carry-over.
- Assessment covers potential sources such as nitrosating agents, amine precursors, solvent/reagent impurities & processing/storage conditions.
- We perform root-cause investigations for any detected nitrosamine to identify origin & corrective actions.
Regulatory expectation: marketing authorization holders must assess nitrosamine risk in products & manufacturing processes.
- Development & validation of robust, stability-indicating analytical methods for trace-level quantitation (GC/MS, LC-MS/MS & other orthogonal techniques), following regulatory validation principles.
- Emphasis on sensitivity (low ng/g or ng/mL levels where required), method specificity, accuracy, precision & system suitability reporting.
- Routine method suitability checks & participation in external proficiency tests where available.
Regulators expect validated methods capable of reliably detecting nitrosamines at or below acceptable intake levels.
- Use of published AIs & where appropriate, compound-specific toxicological data, read-across or SAR approaches to derive acceptable intake limits.
- When compound-specific AIs are absent, we follow current international approaches (FDA/EMA/ICH/EDQM recommendations) to propose scientifically justified limits.
See FDA & EMA recommended acceptable intake approaches & lists of established AIs.
- Process redesign & raw-material controls to eliminate or minimize formation pathways.
- Supplier qualification & detailed incoming material testing for amines, nitrite & related precursors.
- Specification updates, tightened storage/handling SOPs & change control to prevent new risks.
- Use of preventive controls & CAPA following detection.
Regulatory guidance expects risk-based controls & supplier management to prevent nitrosamine presence.
- Longitudinal monitoring of retained samples to evaluate nitrosamine formation over shelf life & under stress/storage conditions.
- Batch release includes nitrosamine screening where risk assessment indicates potential presence.
- Ongoing surveillance & trending to detect shifts in impurity profiles.
- Preparation of risk assessment reports, method validation packages & corrective action documents for regulatory submissions & inspections.
- Support for dossier updates, variations & responses to regulatory queries.
- We align documentation to ICH M7 principles & regional positions (FDA, EMA, EDQM).
- Strict laboratory safety, chemical hygiene and waste-management practices for working with nitroso compounds & suspected precursors.
- Personnel receive targeted training on hazard awareness, sample handling and emergency procedures.
(This section on safety is deliberately non-procedural — it does not provide operational steps).
- Collaborative work with toxicologists, regulatory experts & external laboratories to keep approaches aligned with global best practice.
- Publication & sharing of non-confidential method performance summaries and risk-assessment frameworks with clients on request.
🤝 What We Offer to Clients / Partners
- Comprehensive nitrosamine risk assessments for APIs and finished products.
- Development & validation of trace-level analytical methods (sensitivity & robustness reporting).
- Supplier audits & incoming-material qualification focused on nitrosamine precursors.
- Root-cause investigations & CAPA implementation following any detection.
- Regulatory-grade documentation: AI justification, control strategy, method validation, stability data.
- Retained-sample monitoring programs & shelf-life surveillance.
- Customized training for manufacturing & QA / QC teams on nitrosamine risk awareness.
✅ Why Choose Our R&D Team
- Regulatory-aware: Programs aligned with FDA, EMA, ICH & EDQM expectations.
- Analytical Expertise: Trace-level LC-MS / MS & GC-MS workflows.
- Cross-functional: Toxicology, chemistry, QA / RA, & analytics under one roof.
- Confidential & Audit-ready documentation.
📚 Important Regulatory References
- FDA — Control of Nitrosamine Impurities in Human Drugs (Guidance for Industry). U.S. FDA
- FDA — Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities. U.S. FDA
- EMA — Nitrosamine impurities: guidance and updates for marketing-authorisation holders. EMA
- ICH M7(R2) & addendum — Assessment & control of DNA-reactive (mutagenic) impurities. ICH
- EDQM / Europe updates on N-nitrosamines and Acceptable Intakes. EDQM
📞 Contact & Requests
For technical discussions, to request a risk assessment, COA / MSDS, or to arrange a confidential consultation about nitrosamine control, please contact:
R&D & Technical Enquiries